Steven M. Rowe - Concepedia

Author

Steven M. Rowe

University of Alabama at Birmingham ORCID

Also Known As

Ashlock, Melissa A., Donaldson, Scott H, Elizabeth H. Baker, Hardison, Mathew, Konstan, Michael W, Moss, Rick, Pasek, Raymond C., Ratjen, Felix, Ronald L. Gibson, Rowe, S.

432

Publications

28.8K

Citations

H-Index

181

Concepts

All Affiliations

University of Alabama at Birmingham University of Colorado Denver Cystic Fibrosis Foundation Massachusetts General Hospital University of Washington

About

Steven M. Rowe is an author at University of Alabama at Birmingham specializing in medicine, pulmonary fibrosis, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	39	69	8.9K
2	Engineering	10	10	580
3	Natural Sciences	7	7	285
4	Health Sciences	5	5	377
5	Public Health	3	3	300

Steven M. Rowe

192

Publications

25.3K

Citations

H-Index

Page 1

	Year	Citations
A CFTR Potentiator in Patients with Cystic Fibrosis and the <i>G551D</i> Mutation Bonnie W. Ramsey, Jane C. Davies, Noel G. McElvaney, New England Journal of Medicine	2011	2.1K
Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele Peter G. Middleton, Marcus Mall, Pavel Dřevı́nek, New England Journal of Medicine	2019	2K
Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del<i>CFTR</i> Claire Wainwright, J.S. Elborn, Bonnie W. Ramsey, New England Journal of Medicine	2015	1.6K
Cystic Fibrosis Steven M. Rowe, Stacey Miller, Eric J. Sorscher New England Journal of Medicine FibrosisMendelian DisorderInflammatory Lung DiseaseDisease MechanismGenetic Disorder	2005	1.4K
Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial Harry Heijerman, Edward F. McKone, D.G. Downey, The Lancet Mendelian DisorderGeneticsIvacaftor Combination RegimenF508del MutationMedicine	2019	1.3K
A revised airway epithelial hierarchy includes CFTR-expressing ionocytes Daniel T. Montoro, Adam L. Haber, Moshe Biton, Nature Pulmonary PhysiologyCftr-expressing IonocytesMedicineCell BiologyCellular Physiology	2018	1.2K
Effect of VX-770 in Persons with Cystic Fibrosis and the G551D- <i>CFTR</i> Mutation Frank J. Accurso, Steven M. Rowe, John P. Clancy, New England Journal of Medicine	2010	798
VX-445–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles D. Keating, Gautham Marigowda, Lucy Burr, New England Journal of Medicine	2018	707
Tezacaftor–Ivacaftor in Residual-Function Heterozygotes with Cystic Fibrosis Steven M. Rowe, Cori Daines, Felix C. Ringshausen, New England Journal of Medicine	2017	499
Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the <i>F508del-CFTR</i> mutation John P. Clancy, Steven M. Rowe, Frank J. Accurso, Thorax	2011	493

Page 1